Background: Previous research has shown that infliximab (IFX) is effective in the management of moderate to severe active ulcerative colitis (UC). Latin American studies are lacking. Aim: To evaluate the efficacy of IFX treatment (including corticosteroid withdrawal, complete mucosal healing, colectomy and hospitalization rates) in patients with moderate to severe UC. Methods: A retrospective and descriptive study was conducted on patients with UC in Medellín (Colombia). We included patients steroid dependent or refractory to conventional treatment. Results: Between October 2005 and July 2011, 28 patients with moderate to severe UC received IFX infusions; the median of the follow-up was 27.4 months (range: 1-69 months). Twenty-four patients (86%) had a short-term primary response, whilst 19 (68%) achieved initial clinical remission. After 1 year, 17 (71%) out of the 24 patients who had an initial response were also showing a sustained response, and 10 (42%) remained in clinical remission. At 6 months, complete mucosal healing was observed in 29% of patients and endoscopic improvement in 57%. Conclusions: This is the first study to evaluate the IFX use in patients with moderate to severe active UC in a Latin American population. We found that IFX therapy is effective for inducing clinical remission, and that most patients who had an initial response showed a long-term sustained response.

Journal Section:
Original Paper
Keywords:
Ulcerative colitis, Infliximab, Tumor necrosis factor α, Anti-tumor necrosis factor α
1.
Juliao F, Florez JF, Ruiz MH, et al: Phenotypes and natural history of inflammatory bowel disease (IBD) in a referral population in Medellín, Colombia. Rev Col Gastroenterol 2010;25:240-251.
2.
Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al: The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study. Gastroenterology 2001;121:255-260.
[PubMed]
https://doi.org/10.1053/gast.2001.26279
3.
Langholz E, Munkholm P, Davidsen M, Binder V: Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444-1451.
[PubMed]
4.
Penna C, Dozois R, Tremaine W, et al: Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234-239.
[PubMed]
5.
Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-1709.
[PubMed]
6.
Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT: Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
[PubMed]
https://doi.org/10.1016/0140-6736(92)90999-J
7.
Rutgeerts P, Sandborn WJ, Feagan BG, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
[PubMed]
https://doi.org/10.1056/NEJMoa050516
8.
Sandborn WJ, Rutgeerts P, Feagan BG, et al: Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-1260.
[PubMed]
https://doi.org/10.1053/j.gastro.2009.06.061
9.
Gisbert JP, Gonzalez-Lama Y, Mate J: Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007;25:19-37.
[PubMed]
https://doi.org/10.1111/j.1365-2036.2006.03131.x
10.
Stange EF, Travis SPL, Vermeire S, et al: European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008;2:1-23.
[PubMed]
https://doi.org/10.1016/j.crohns.2007.11.001
11.
Satsangi J, Silverberg MS, Vermeire S, et al: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753.
[PubMed]
https://doi.org/10.1136/gut.2005.082909
12.
Papa A, Mocci G, Bonizzi M, et al: Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol 2009;104:1575-1586.
[PubMed]
https://doi.org/10.1038/ajg.2009.162
13.
Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987;317:1625-1629.
[PubMed]
https://doi.org/10.1056/NEJM198712243172603
14.
Panaccione R, Rutgeerts P, Sandborn WJ, et al: Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:674-688.
[PubMed]
https://doi.org/10.1111/j.1365-2036.2008.03753.x
15.
Ferrante M, Vermeire S, Fidder H, et al: Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn's Colitis 2008;2:219-225.
[PubMed]
https://doi.org/10.1016/j.crohns.2008.03.004
16.
Gonzalez-Lama Y, Fernandez-Blanco I, López-San Roman A, et al: Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008;55:1609-1614.
[PubMed]
https://doi.org/10.1016/S1873-9954(07)70040-X
17.
Barreiro M, Lorenzo A, Dominguez-Munoz E, et al: W1121 clinical efficacy and mucosal healing rate of infliximab in steroid-dependent ulcerative colitis: a prospective long-term follow-up study. Gastroenterology 2009;136:A-658.
https://doi.org/10.1016/S0016-5085(09)63035-3
18.
Panaccione R, Ghosh S, Middleton S, et al: Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohn's Colitis 2011;5:13.
19.
Oussalah A, Evesque L, Laharie D, et al: A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010;105:2617-2625.
[PubMed]
https://doi.org/10.1038/ajg.2010.345
20.
Oussalah A, Danese S, Peyrin-Biroulet L: Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 2009;11:156-175.
[PubMed]
https://doi.org/10.2174/138945010790309939
© 2013 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2013
You do not currently have access to this content.